Related Experiment Video

Updated: May 17, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

RANTES gene G-403A polymorphism and coronary artery disease: a meta analysis of observational studies

Jun Liu1, Yan-Jun Jia, Xiao-Lin Li

  • 1Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

Plos One
|October 17, 2012
PubMed

Insights

This meta-analysis found no significant link between the RANTES G-403A polymorphism and coronary artery disease (CAD) risk overall. Further research with larger sample sizes and standardized methods is needed to clarify potential ethnic differences.

Area of Science:

  • Genetics and Cardiovascular Disease Research
  • Molecular Biology and Disease Mechanisms

Background:

  • The RANTES gene's G-403A polymorphism is hypothesized to influence coronary artery disease (CAD) development by affecting leukocyte activity.
  • Previous studies on the G-403A polymorphism and CAD risk have produced conflicting results, necessitating further investigation.

Purpose of the Study:

  • To conduct a meta-analysis to clarify the association between the RANTES G-403A polymorphism and CAD susceptibility.
  • To resolve inconsistencies in existing research regarding this genetic variation and heart disease risk.

Main Methods:

  • A comprehensive literature search was performed across PubMed and EMBASE databases up to March 2012.
  • Additional studies were identified through citation reviews and author contact to ensure a thorough analysis.
  • Meta-analysis was employed to synthesize data from 8 eligible studies involving 4252 CAD cases and 2150 controls.

Main Results:

  • No significant association was found between the G-403A polymorphism and CAD risk across various genetic models.
  • Significant heterogeneity among studies was identified, potentially explained by ethnicity and genotyping methods.
  • Stratified analysis suggested a possible association with increased CAD risk in Caucasians and a protective role in Asians, though not consistently.

Conclusions:

  • Current meta-analysis data do not support a direct relationship between the RANTES G-403A polymorphism and CAD development.
  • Larger studies utilizing unified genotyping methods are recommended to definitively assess the influence of this polymorphism on CAD susceptibility.
Abstract

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...